Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Case Series of 36 Patients Treated for Old World Cutaneous Leishmaniasis



Saffarian Z1 ; Marandi ZV2 ; Shakoei S1 ; Hamzelou S1 ; Rafati S3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Dermatology Department, Imam Khomeini Hospital Complex, Razi Dermatology Hospital, Tehran University of Medical Science, Tehran, Iran
  2. 2. Dermatology Department, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Science, Tehran, Iran
  3. 3. Department of Immunotherapy and Leishmania Vaccine Research, The Pasteur Institute of Iran, Tehran, Iran

Source: Journal of Clinical and Aesthetic Dermatology Published:2024

Abstract

BACKGROUND: Cutaneous leishmaniasis is endemic in Iran. OBJECTIVE: We sought to investigate the therapeutic outcomes and complications of treatment in patients with cutaneous leishmaniasis. METHODS: This case series enrolled patients with smear-proven cutaneous leishmaniasis who visited our center in Iran from 2018 to 2019. RESULTS: In total, 36 patients were treated with intralesional meglumine antimoniate, intramuscular meglumine antimoniate, sodium stibogluconate, and amphotericin B. Overall, this treatment was effective in 81.8 percent of patients. Relapse and treatment failure occurred in 6.1 percent and 12.1 percent of patients, respectively. Treatment with intralesional meglumine antimoniate, intramuscular meglumine antimoniate, sodium stibogluconate, and amphotericin B yielded a clearance rate of 80.8 percent, 92.3 percent, 75 percent, and 85.7 percent, respectively. Clearance was associated with a shorter time interval between injections of intralesional meglumine antimoniate (p=0.006) and relapse was associated with a longer time interval between injections (p=0.018). The average number of side effects per patient for intralesional meglumine antimoniate, sodium stibogluconate, intramuscular meglumine antimoniate, and amphotericin B was 0.62, 1.4, 1.6, and 2.8, respectively. The most common side effect of intralesional meglumine antimoniate, intramuscular meglumine antimoniate, and amphotericin B was local pain, arthralgia, and hypokalemia, respectively. LIMITATIONS: Low sample size was the limitation of this study. CONCLUSION: The cure rate of intramuscular meglumine antimoniate was higher than amphotericin B, which was higher than the cure rate of sodium stibogluconate. In patients treated with intralesional meglumine antimoniate, reducing the time interval between injections increased the clearance rate and decreased the rate of relapse. © 2024 Matrix Medical Communications. All rights reserved.
Related Docs
View other Related Docs
1. Efficacy of Intra-Lesional Injections of Meglumine Antimoniate Once a Week Vs. Twice a Week in the Treatment of Cutaneous Leishmaniasis Caused by L. Tropica in Iran: A Randomized Controlled Clinical Trial, PLoS Neglected Tropical Diseases (2022)
2. Old World Cutaneous Leishmaniasis in Iran: Clinical Variants and Treatments, Journal of Dermatological Treatment (2021)
3. Molecular Identification of Leishmania Species in a Re-Emerged Focus of Cutaneous Leishmaniasis in Varamin District, Iran, Journal of Arthropod-Borne Diseases (2017)
4. The Effects of Leishmania Rna Virus 2 (Lrv2) on the Virulence Factors of L. Major and Pro-Inflammatory Biomarkers: An in Vitro Study on Human Monocyte Cell Line (Thp-1), BMC Microbiology (2023)
5. An Alphavirus-Derived Self-Amplifying Mrna Encoding Ppsp15-Lmsti1 Fusion Protein for the Design of a Vaccine Against Leishmaniasis, Parasitology International (2022)
6. Field Efficacy of Topical Nano-Liposomal Amphotericin B (Sina Ampholeish®) Alone or in Combination With Glucantime® and Cryotherapy on Human Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2023)
7. Molecular Epidemiological Survey of Cutaneous Leishmaniasis in Two Highly Endemic Metropolises of Iran, Application of Fta Cards for Dna Extraction From Giemsa-Stained Slides, Jundishapur Journal of Microbiology (2016)
8. Presence and Diversity of Leishmania Rna Virus in an Old Zoonotic Cutaneous Leishmaniasis Focus, Northeastern Iran: Haplotype and Phylogenetic Based Approach, International Journal of Infectious Diseases (2020)
Experts (# of related papers)
View all Related Experts
Mahdi Mohebali (14)
Alireza Firooz (6)
Other Related Docs
9. Antimonial Treatment Failure Rate in Patients With Cutaneous Leishmaniasis, Tehran University Medical Journal (2018)
10. Global Dilemma and Needs Assessment Toward Achieving Sustainable Development Goals in Controlling Leishmaniasis, Journal of Epidemiology and Global Health (2024)
11. A Comparison Between the Effects of Glucantime, Topical Trichloroacetic Acid 50% Plus Glucantime, and Fractional Carbon Dioxide Laser Plus Glucantime on Cutaneous Leishmaniasis Lesions, Dermatology Research and Practice (2016)
12. Safety Evaluation of Topical Application of Nano-Liposomal Form of Amphotericin B (Sinaampholeish) on Healthy Volunteers: Phase I Clinical Trial, Iranian Journal of Parasitology (2019)
13. Associated-Risk Determinants for Anthroponotic Cutaneous Leishmaniasis Treated With Meglumine Antimoniate: A Cohort Study in Iran, PLoS Neglected Tropical Diseases (2019)
14. Harmonized Clinical Trial Methodologies for Localized Cutaneous Leishmaniasis and Potential for Extensive Network With Capacities for Clinical Evaluation, PLoS Neglected Tropical Diseases (2018)
15. Comparative Expression Profile Analysis of Apoptosis-Related Mirna and Its Target Gene in Leishmania Major Infected Macrophages, Iranian Journal of Parasitology (2020)
16. Vector and Reservoir Control for Preventing Leishmaniasis, Cochrane Database of Systematic Reviews (2015)
17. Molecular Detection of Leishmania Major and L. Turanica in Phlebotomus Papatasi and First Natural Infection of P. Salehi to L. Major in North-East of Iran, Journal of Arthropod-Borne Diseases (2016)
18. Study on Knowledge, Attitude and Practice of Health Workers of East Azerbaijan, Ilam and Khorasan Razavi Provinces About Leishmaniasis During 2015-2016: A Comparative Study Before and After Intervention, Archives of Clinical Infectious Diseases (2019)
19. Economic Burden of Cutaneous and Visceral Lishmaniasis in Iran in 2013, Iranian Journal of Epidemiology (2017)
20. Pilot Study of Safety and Efficacy of Topical Liposomal Amphotericin B for Cutaneous Leishmaniasis Caused by Leishmania Major in Islamic Republic of Iran; [Etude Pilote Sur L'innocuite Et L'efficacite De L'amphotericine B Liposomale Topique Pour Le Traitement De La Leishmaniose Cutanee Causee Par Leishmania Major En Republique Islamique D'iran], Eastern Mediterranean Health Journal (2022)
21. The Role of Atp-Binding Cassette Transporter Genes Expression in Treatment Failure Cutaneous Leishmaniasis, AMB Express (2022)
22. Anti-Leishmanial Effects of Resveratrol and Resveratrol Nanoemulsion on Leishmania Major, BMC Microbiology (2022)
23. Immunotherapeutic Effects of Glycyrrhiza Glabra and Glycyrrhizic Acid on Leishmania Major-Infection Balb/C Mice, Parasite Immunology (2022)
24. An Overview of Leishmanization Experience: A Successful Control Measure and a Tool to Evaluate Candidate Vaccines, Acta Tropica (2019)
25. Prevalence Estimates of Human Immunodeficiency Virus (Hiv) Infection Among Visceral Leishmaniasis Infected People in Northwest Ethiopia: A Systematic Review and Meta-Analysis, BMC Infectious Diseases (2020)
26. Comparative Proteomic Profiling of Leishmania Tropica: Investigation of a Case Infected With Simultaneous Cutaneous and Viscerotropic Leishmaniasis by 2-Dimentional Electrophoresis and Mass Spectrometry, Iranian Journal of Parasitology (2015)
27. Biophysical and Ultrasonographic Changes of Acute Old World Cutaneous Leishmaniasis Skin Lesions in Comparison With Uninvolved Skin: A Possible Tool for Non-Invasive Early Detection and Treatment Outcome Assessment, Dermatologic Therapy (2022)